Abstract: Methods for using an anti-CD19 antibody to treat autoimmune disease are disclosed herein. In particular the use of VIB551, a humanised, affinity-optimised, afucosylated IgG1 kappa monoclonal antibody to treat Neuromyelitis optica spectrum disorder.

Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: The invention is directed to a chimeric antigen receptor (CAR) directed against CD19, which comprises an amino acid sequence of any one of SEQ ID NO: 1-SEQ ID NO: 13. The invention also provides T-cells expressing the CAR and methods for destroying malignant B-cells.

Abstract: The present invention relates to a method of treating Burkitt lymphoma or leukemia in a patient, the method comprising administering to said patient a composition comprising a CD19×CD3 bispecific antibody in at least one treatment cycle, wherein the treatment cycle comprises administering a first dose of 15 ?g/m2/d of the CD19×CD3 bispecific antibody for a first period of time of 4 days, and administering after the first dose a second dose of 60 Kg/m2/d of the CD19×CD3 bispecific antibody for a second period of time, wherein the second period of time exceeds the first period of time.

Abstract: There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.

Abstract: Disclosed herein are novel PD1 binding molecules and methods of their use.

Abstract: Disclosed herein are antibodies that bind to PD-1, comprising one or more CDRs selected from the amino acid sequences of SEQ ID NOs: 13, 14, 15, 16, 17, and 18. The antibodies have high affinity and low dissociation rate for PD-1, as well as the activity for neutralizing PD-1 in vitro. The antibodies disclosed herein can be full-length antibodies or antigen-binding fragments thereof. The antibodies can be used for detecting PD-1 and the like.

Abstract: The present invention is directed to bispecific, heterodimeric checkpoint antibodies.

Abstract: The present invention is directed to a combination therapy involving the administration of a first molecule that specifically binds to human B7-H3 and a second molecule that that specifically binds to human PD-1 to a subject for the treatment of cancer and/or inflammation. The invention also concerns pharmaceutical compositions that comprise a first molecule that specifically binds to human B7-H3 and a second molecule that specifically binds to human PD-1 that are capable of mediating, and more preferably enhancing, the activation of the immune system against cancer cells that are associated with any of a variety of human cancers. The invention also relates to the use of such pharmaceutical compositions to treat cancer and other diseases in recipient subjects.

Abstract: Provided is a bispecific fusion protein having a novel structure. A second binding structural domain is inserted into an IgG hinged region in a full length by means of an optional peptide joint. The fusion protein has the same expression and production advantages as those of IgG, does not influence the binding activity of an Fab region of the fusion protein and further improves the stability and obtains a higher half life. In addition, the binding activity of the second binding structural domain to a target binding site is significantly improved with respect to the binding activity of a monomer corresponding to a soluble natural binding fragment to a corresponding target.

Abstract: Provided are multi-specific antibodies that target both a cellular efflux pump and a cancer-associated antigen as well as pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such multi-specific antibodies. Methods of treating a subject for a cancer that include administering to the subject a multi-specific antibody that targets both a cellular efflux pump and a cancer-associated antigen are also provided. Provided as well are methods of generating the described multi-specific antibodies and reagents related thereto, including genetically modified cell lines useful in the subject methods and methods of making such genetically modified cell lines.

Abstract: The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-?)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment.

Abstract: Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.

Abstract: An antibody or an antigen-binding fragment thereof is capable of specifically recognizing TrkA and uses thereof. The antibody contains a CDR sequence selected from at least one of the following or an amino acid sequence having at least 95% identity with it: heavy chain variable region CDR sequences: SEQ ID NO: 1˜27, light chain variable region CDR sequences: SEQ IN NO: 28˜54. The above antibody can specifically targeted-bind to the TrkA receptor and block the binding of NGF to TrkA.

Abstract: The present invention provides methods for decreasing a nasal polyp score in a subject. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.

Abstract: The present disclosure provides compositions and methods for extended release of certain types of antibodies in vivo. It was discovered that such antibodies are able to initiate reversible gelation of hyaluronic acid (HA) by creating a depot that dissociates over time to release the antibody without any impact on its physical and chemical properties as well as its biological activity. As certain tissues and organs, such as eyes, joints and skins, contain HA, local injection of the antibodies to these tissues or organs will result in embedding of the antibody in gel formed from the HA, which becomes a repository of slow-released antibodies. In addition, slow-released formulations can be prepared with antibodies mixed with HA, optionally with other polymers.

Abstract: A polypeptide comprising a crystallizable fragment (Fe) region of IgG for use in prevention or treatment of a disease, in particular of a disease affecting the central nervous system. The polypeptide is administered locally to compartments, in particular to the central nervous system. The Fe region comprises the mutations I253N and H435Q and an H at position 310 resulting in reduced affinity to the neonatal Fe receptor (FeRn), resulting in an increased brain to serum concentration of the polypeptide.

Abstract: The present invention provides monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to NPR1. In some embodiments, the antibodies of the invention are useful for activating NPR1 activity, thus providing a means of treating or preventing a disease, disorder or condition associated with NPR1 in humans.

Abstract: The present invention relates to silent Fc variants of anti-CD40 antibodies and compositions and methods of use of said antibodies for treating pathological disorders such as autoimmune and inflammatory disorders and/or for preventing or reducing the risk of graft rejection in transplantation.

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.

Abstract: Disclosed herein are combination therapies comprising daratumumab and their uses.

Abstract: This disclosure is in the field of cancer immunotherapy and relates to all cancer types, including but not limited to cancers of the breast, lung, prostate, pancreas, colon, bladder, brain, head-neck, kidney, esophagus, skin, and blood cells. The embodiments provide methods for selecting and amplifying specific targeting molecules to use in therapy and diagnostic testing. Targets include but are not necessarily limited to architecturally preserved, usually heterogeneous specific surface structures present on individual cancer cells and cancer stem cells but not on non-malignant cells. The embodiments are novel in that they provide these binding molecules for one individual's cancer regardless of the rarity of an individual cancer cell or stem cell and promptly enough to initiate treatment without requiring lengthy immunization or hybridoma production that are current art.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: The present invention provides a novel class of antibodies and antigen binding fragments thereof that bind the extracellular domain of ErbB3 receptor and inhibit various ErbB3 functions. For example, the antibodies and antigen binding fragments described herein are capable of binding to the receptor designated ErbB3 and inhibiting EGF-like ligand mediated phosphorylation of the receptor. Such antibodies and antigen binding fragments thereof have the useful characteristic of inhibiting the proliferation of cancer cells expressing ErbB3.

Abstract: The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the diagnosis of a cancer or a metastasis thereof. The disclosure herein relates to novel cancer-associated antibodies and antigen-binding fragments that are used in the treatment of a cancer or a metastasis thereof. The disclosure herein relates to novel chimeric antigen receptor or a T cell receptor fusion protein that comprise one or more cancer-associated antigen-binding domains that are useful for the treatment of a cancer.

Abstract: The present invention is directed to HER2 antibodies directed against an epitope between amino acids 342-652 of human HER2 for use in the treatment of HER2 related disorders in combination with a second HER2 inhibitor. More specifically the invention relates to methods and uses of MAB270 or antibodies having the same CDRs as MAB270 in combination with trastuzumab or pertuzumab in HER2 positive cancer.

Abstract: Compositions and methods of using antibodies that are able to recognize single amino acid polymorphisms in a protein are provided. Compositions are disclosed which may be used for blood typing or to block hemolytic transfusion reactions and/or hemolytic disease of the fetus and newborn.

Abstract: Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.

Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.

Abstract: The present disclosure relates to the technical field of biomedicine, and provides an anti-physaliatoxin nanobody, and a preparation method and use thereof. The nanobody is a VHH antibody with an amino acid sequence shown in SEQ ID NO. 1. Affinity analysis shows that the nanobody of the present disclosure has prominent affinity. It is proved by small animal experiments that, after mice in an antibody protection group pre-injected with the nanobody of the present disclosure are injected with physaliatoxin, no mice shows toxic symptoms, and during continuous observation for one month, no toxic lethality occurs, indicating that the nanobody of the present disclosure shows excellent anti-physaliatoxin effects, excellent preventive or therapeutic effects on jellyfish stings, and promising clinical application prospects.

Abstract: Disclosed is a method for improving affinity of an antibody for an antigen, the method comprising: in the antibody, changing at least 3 amino acid residues of framework region 3 (FR3) as defined by Kabat method to arginine residues or lysine residues, thereby improving affinity of an antibody for an antigen as compared with that of an antibody before said at least 3 amino acid residues are changed to arginine residues or lysine residues, wherein said at least 3 amino acid residues comprise at least 3 selected from the group consisting of amino acid residues at positions 68, 70, 72, 74, 75, 77, 79, 81, 82A, 82B, 83, 84, 85 and 87 of a heavy chain as defined by the Kabat method.

Abstract: In some embodiments, a bioelectronic device includes an electrode, target proteins, and attachment mechanisms that immobilize the target proteins on the electrode, the attachment mechanisms comprising linker proteins that interface with the target proteins and attach the target proteins to the electrode.

Abstract: The invention relates to a method for the preparation of micro- or nano crystalline cellulosic compositions from virgin cellulose containing amorphous and crystalline cellulose phases comprising the following steps: (A) contacting virgin cellulose with a first solvent, characterized in that the first solvent is an aqueous solution comprising 40-65 wt. % ZnCl2 in water, relative to the total weight of the of ZnCl2 and water, (B) dissolving the amorphous cellulosic phase, whereby the amorphous cellulosic phase is preferentially dissolved over the crystalline cellulosic phase, (C) separating the dissolved amorphous cellulose from the crystalline cellulose and preferably step C wherein the obtained micro- or nanocellulose has XRD type I structure, which then can be contacted with a second solvent comprising between 65 and 90 wt. % ZnCl2 in water to produce delaminated cellulose having XRD type II structure.

Abstract: The present invention provides a method for removing an organic solvent from starch hemostatic microspheres, comprising the following steps: 1. taking to-be-dried starch hemostatic microspheres and laying them flatly on drying trays with attention to laying them as uniformly and thinly as possible; 2. taking an adsorbent and subpackaging it into dialyzing paper bags for sealing; and 3. placing the trays and the dialyzing paper bags completed in the previous two steps on separators of a low-temperature vacuum oven in layers, setting the oven temperature at 0-20° C., then vacuumizing and keeping pressure for 15-48 hours. The method provided by the present invention can reduce organic solvent residue in the starch hemostatic microspheres to less than 0.05%, which meets the requirements of relevant standards for medical devices, thereby improving safety of products.

Abstract: Through sourcing net-primary productivity additive algae-based biomass feedstock, the exclusive use of renewable energy in processing, and the appropriate formulation and processing, a novel algae-derived bio-based plastic is both carbon-negative and provides some performance advantages over existing algae-based film plastics especially with regard to optical clarity. A system may be provided that produces a carbon-negative bioplastic. The production of the bioplastic in a process chamber may be controlled by an electronic controller. The electronic controller may be controlled by a host system, such a server. The electronic controller may be configured to direct production of the bioplastic in the process chamber using hydrocolloid, which is derived from algae.

Abstract: Provided herein are new cyclodextrin-based compounds, and pharmaceutically acceptable salts, stereoisomers, and isotopically labeled derivatives thereof, which are capable of binding sugars (e.g., glucose). The compounds provided herein may be conjugated to agents or tags (e.g., therapeutic agents such as insulin) to form conjugates. In another aspect, also provided herein are pharmaceutical compositions comprising the compounds and conjugates described herein. The compounds and conjugates described herein are capable of binding glucose; therefore, provided herein are methods of sensing or detecting glucose comprising contacting glucose with the compound or conjugate. In another aspect, also provided herein are methods of treating a disease (e.g., a metabolic disorder, such as diabetes) in a subject comprising administering to the subject a compound, conjugate, or composition provided herein.

Abstract: The present disclosure pertains to iodinated polysaccharide compounds that comprise a polysaccharide backbone that comprises a plurality of carboxyl groups and a plurality of iodinated side groups. The present disclosure also pertains iodinated polysaccharide compounds in which at least a portion of carboxyl groups that are present in a carboxyl-containing polysaccharide chain are functionalized with a plurality of iodinated side groups. Other aspects of the present disclosure pertain to methods of forming iodinated polysaccharide compounds, medical compositions comprising iodinated polysaccharide compounds, medical procedures comprising introducing such medical compositions into or between tissue of a patient, and medical kits that comprise such medical compositions.

Abstract: A depolymerizer is formed by grafting thiol groups on parts of the double bonds of a polymer of linear conjugated diene monomer. The linear conjugated diene monomer can be 1,3-butadiene, isoprene, 1,3-pentadiene, 2,3-dimethyl-1,3-butadiene, 2-methyl-1,3-pentadiene, 2,3-dimethyl-1,3-pentadiene, 2-phenyl-1,3-butadiene, or 4,5-diethyl-1,3-octadiene. The depolymerizer has a weight average molecular weight of 1000 to 400000.

Abstract: A desulfurized rubber obtained by mixing a desulfurization agent and a vulcanized rubber, the desulfurization agent containing a compound represented by any one of the following formulae (1) to (4): wherein R1 to R8 each independently represent a hydrogen atom, an oxygen atom, or an alkyl group. It is preferable that the desulfurization agent contains at least one selected from the group consisting of 2,2?-dithiodianiline and 4,4?-dithiodianiline.

Abstract: A method for producing a perfluoroelastomer, which includes carrying out polymerization of a perfluoromonomer in an aqueous medium in the presence of a polymer (1) having a number average molecular weight of 0.3×104 or more to provide a perfluoroelastomer, the polymer (1) containing a polymerized unit (1) derived from a monomer represented by the following general formula (1): CX2?CY(—CZ2—O—Rf-A) ??(1) wherein X, Y, Z, Rf and A are as defined herein, with the proviso that at least one of X, Y, and Z contains a fluorine atom.

Abstract: A photocurable coraposition can comprise a polyme.aizable material and a photoinitiator, wherein the polymerizahle material can comprise at least one acrylate monomer including at least one cyano group (CN-acrylate monomer). The presence of a low amount of the CN-acrylate monomer between 10 wt% and not greater than 30 wt% can lower the contact angle of the composition and may improve the etch resistance of a photo-cured layer made from the photocurable composition.

Abstract: Photocurable (meth)acrylate compositions for forming features on the surfaces of membranes, and particularly, on membranes used in osmosis and reverse-osmosis applications, such as membrane filters.

Abstract: The present application relates to a polypropylene with high melt flow index and a method for producing the same, and meltblown fiber fabrics. A reacting mixture is firstly provided, and a polymerization process is performed to the reacting mixture in a slurry reaction system to obtain the polypropylene. The reacting mixture includes propylene monomers, Ziegler-Natta catalysts, organoaluminum compounds and electron donor. The polypropylene has high melt flow index and adjustable melting point and molecular weight distribution, such that it is used to produce the meltblown fiber fabrics.

Abstract: A polymeric article comprises an elastomeric layer comprising cured synthetic polyisoprene particles that comprise a Ziegler-Natta catalyzed polyisoprene.

Abstract: Bio-based ethanol, such as ethanol produced from lignocellulosic materials, for example, is processed to produce bio-based ethylene, which can then be processed further to produce other bio-based materials including bio-based polymers and copolymers, including bio-based polyethylene, bio-based ?-olefins, bio-based 1,2-diols, as well as other compounds.

Abstract: A modifier useful for modifying a polymer providing a functional group having affinity with a filler, particularly, a silica-based filler is provided. A modified conjugated diene-based polymer including a functional group derived from the modifier having excellent affinity with a filler and improved compounding properties, and a method for preparing the same are also provided.

Abstract: The present invention relates to a propylene polymer composition comprising a long chain branched propylene polymer, wherein said propylene polymer composition has a) a crystallization temperature Tc of less than 115° C., b) a melting temperature Tm of less than 155° C. c) a F30 melt strength of from 5.0 to less than 30.0 cN, and d) a V30 melting extensibility of more than 190 mm/s, a process for producing said propylene polymer composition by reactive modification of a propylene polymer in the presence of a peroxide, an article comprising said propylene polymer composition, the use of said propylene polymer composition for producing an article.

Abstract: The present invention relates to a method for producing a copolymer, the method for producing a copolymer including: step (S10) for adding aromatic vinyl-based monomers substituted with alkyl groups and vinyl cyan-based monomers to perform polymerization in the presence of a polymerization initiator, wherein the vinyl cyan-based monomers are collectively added before initiation of the polymerization in step (S10), monomer droplets are continuously divisionally added during the polymerization in step (S10), and the monomer droplets contain part or all of the aromatic vinyl-based monomers substituted with alkyl groups, and relates to a copolymer produced therefrom, and a thermoplastic resin composition including the same.